Cabozantinib
- Generic Name
- Cabozantinib
- Brand Names
- Cabometyx, Cometriq
- Drug Type
- Small Molecule
- Chemical Formula
- C28H24FN3O5
- CAS Number
- 849217-68-1
- Unique Ingredient Identifier
- 1C39JW444G
- Background
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formu...
- Indication
⑴治疗进展的、不能切除的局部晚期或转移的髓性甲状腺癌。
⑵用于舒尼替尼（索坦）治疗失败的晚期肾癌。
- Associated Conditions
- Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Metastatic Differentiated Thyroid Cancer, Locally advanced Differentiated Thyroid Cancer (DTC), Metastatic Clear Cell Renal Cell Carcinoma (ccRCC), Progressive, metastatic Medullary thyroid cancer
- Associated Therapies
- -
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT02592356
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)
- Conditions
- Interventions
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2024-06-17
- Target Recruit Count
- 110
- Registration Number
- NCT02293980
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸University of Pittsburg Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸Virginia Cancer Specialists, Fairfax, Virginia, United States
Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2021-05-20
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 36
- Registration Number
- NCT02260531
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Ph II CABOGIST in GIST
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2021-07-15
- Target Recruit Count
- 51
- Registration Number
- NCT02216578
- Locations
- 🇫🇷
Institut Bergonie (228), Bordeaux, France
🇨🇿University Hospital Motol (1905), Prague, Czechia
🇫🇷Centre Leon Berard (227), Lyon, France
Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Liza Villaruz, MD
- Target Recruit Count
- 5
- Registration Number
- NCT02132598
- Locations
- 🇺🇸
University of Pittsburgh Cancer Institute- Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults
- Conditions
- Interventions
- First Posted Date
- 2014-04-02
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 45
- Registration Number
- NCT02101736
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting
- Conditions
- Interventions
- First Posted Date
- 2014-01-22
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 43
- Registration Number
- NCT02041260
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 8
- Registration Number
- NCT02036476
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer
- First Posted Date
- 2013-12-11
- Last Posted Date
- 2021-02-12
- Lead Sponsor
- John Strickler, M.D.
- Target Recruit Count
- 29
- Registration Number
- NCT02008383
- Locations
- 🇺🇸
Duke Cancer Center, Duke University Medical Center, Durham, North Carolina, United States
Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-11-26
- Last Posted Date
- 2015-02-20
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 54
- Registration Number
- NCT01995058
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.